Lantheus Medical Technologies (LAES) is trading at $3.50 with $420M cash despite having mandated post-quantum cryptography hardware that could unlock significant value. The key risks include execution delays on quantum-resistant technology adoption, competitive threats from larger players, and regulatory timelines that may not align with current stock pricing.

Lantheus Medical Technologies (LAES) is trading at $3.50 with $420M cash, positioning it as a potential post-quantum computing hardware play that few investors are monitoring. Key risks include the speculative nature of quantum-resistant technology adoption timelines, execution risks in scaling production, and potential dilution from financing needs.